Summit Therapeutics Inc. (SMMT) Return on equity 2018–2024
Summit Therapeutics Inc. (SMMT) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-56.9%FY2024 · since FY2018: 18.9% → -56.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -56.9% | +734.6 pp |
| FY2023 | -791.5% | -729.3 pp |
| FY2022 | -62.2% | +44.2 pp |
| FY2021 | -106.4% | -40.1 pp |
| FY2020 | -66.3% | — |
| FY2018 | 18.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More SMMT financial trends
SMMT RevenueSMMT Net incomeSMMT Net marginSMMT Gross profitSMMT Gross marginSMMT Operating incomeSMMT Operating marginSMMT Operating cash flowSMMT Free cash flowSMMT Capital expendituresSMMT Stock buybacksSMMT Dividends paidSMMT Total assetsSMMT Total liabilitiesSMMT Shareholders’ equitySMMT overview →